News

NCX 470 0.1% achieved an intraocular pressure of less than or equal to 18 mmHg compared to latanoprost 0.005% in the trial.

Neurologist warns about recurrent optic neuritis attacks.

ENCELTO is the first and only FDA-approved treatment for MacTel.

At the EnVision Summit 2025, medical students were given awards for best poster presentation. In exclusive interviews, they spoke with Ophthalmology Times about their award-winning posters and research.

Survey examines experiences and perceptions of patients living with GA.

The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type.”

To tackle systemic barriers to eye care, the organization is co-hosting an event titled “No Woman Left Behind – Advancing Eye Health Equity for Women and Girls” on Tuesday, March 11, 2025, at the 69th Commission on the Status of Women in New York.

Inflammation and scarring are the primary obstacles with pirfenidone.

ABI-201 aims to prevent dry AMD and other retinal disorders in patients.

At the EnVision Summit 2025 in San Juan, Puerto Rico, Poonam Misra, MD, and Alcina Lidder, MD, gave advice on managing glaucoma in patients with other ocular co-morbidities such as myopia and those who have undergone corneal transplantation.

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly indicated for severe acute and chronic allergic and inflammatory conditions affecting the eye.

The negative effects of smoking on ocular tissues are well known and include age-related macular degeneration (AMD), diabetic retinopathy, cataracts, contact lens-related keratitis, Graves’ ophthalmopathy ischemic optic neuropathy, and glaucoma.

Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette and is designed to be administered as a one-time intravitreal injection.

Sophisticated programs require an evolving mindset.

Clinician-scientists play a vital role in advancing ophthalmology by balancing patient care with research, leveraging clinical insights to drive impactful discoveries, and collaborating across disciplines to stay at the forefront of innovation.

At the Envision Summit 2025 in San Juan, Puerto Rico, Amy Zhang, MD, discussed the importance of ergonomics in the operating room.

At the EnVision Summit 2025 in San Juan, Puerto Rico, Tania Tai, Lucy Shen, and Shivani Kamat all gave insight into complications they have seen while performing glaucoma surgery.

The investigators set out to identify a correlation between the TyG index in CRAO in patients who had been newly diagnosed with the disease.

Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including Alzheimer disease and dementia with Lewy bodies.

These tools help fill a gap that current technologies cannot achieve as effectively.

The aim of the study was to assess the effect of a modified TCLB procedure that added deframing and decompression maneuvers to the LOFC and its support structures to obtain better results for both the lower and upper lids.

Researchers conducted a first-of-a-kind cross-sectional study at the outpatient clinic of the Eye Hospital of China Academy of Chinese Medical Sciences from March to June 2024

The research analyzed the 1-year outcomes of 132 eyes, evaluating mean IOP, baseline changes, medication reduction, and stratifying the results by race (African American vs Caucasian) and glaucoma severity (mild, moderate, severe).

Toric IOLs outperform femtosecond laser-assisted astigmatic keratotomy in reducing postoperative astigmatism and improving UDVA after cataract surgery.

Meibomian glands are critical to the ocular health in that they secrete lipid-rich meibum, which protects the ocular surface by preventing tear film evaporation.

What do ophthalmologists consider the key advancements in treating glaucoma over the last several decades?

Emerging technologies, such as remote tonometry and genetic risk scoring, are revolutionizing glaucoma care by enabling earlier detection, personalized management, and more efficient use of resources.

If approved, the drug will be branded as LYTENAVA.